[go: up one dir, main page]

Drug Therapy, Combination

"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
Therapy with two or more separate preparations given for a combined effect.


expand / collapse Publications
This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.
Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.
  1. Allopregnanolone as an Adjunct Therapy to Midazolam is More Effective Than Midazolam Alone in Suppressing Soman-Induced Status Epilepticus in Male Rats. CNS Neurosci Ther. 2025 Mar; 31(3):e70215.
    View in: PubMed
  2. Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar; 31(3):467-476.
    View in: PubMed
  3. Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. Blood. 2025 Feb 20; 145(8):811-822.
    View in: PubMed
  4. Trial protocol of an open-label pilot study of oral naltrexone-bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial). BMJ Open. 2025 Feb 07; 15(2):e092032.
    View in: PubMed
  5. Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19. Clin Infect Dis. 2025 Feb 05; 80(1):63-71.
    View in: PubMed
  6. Selection and prioritization of candidate combination regimens for the treatment of tuberculosis. Sci Transl Med. 2025 Feb 05; 17(784):eadi4000.
    View in: PubMed
  7. Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study. RMD Open. 2025 Jan 30; 11(1).
    View in: PubMed
  8. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med. 2025 Jan 30; 392(5):468-482.
    View in: PubMed
  9. Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial. Diabetes Care. 2025 Jan 01; 48(1):52-60.
    View in: PubMed
  10. Diuretic Potentiation Strategies in Acute Heart Failure. JACC Heart Fail. 2025 Jan; 13(1):14-27.
    View in: PubMed